Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Diagnosis of 1 of the following:

- CLL or SLL, relapsed or refractory

- Indolent B-cell lymphoma, relapsed or refractory:

- Follicle center lymphoma, follicular or diffuse

- Marginal zone B-cell lymphoma (splenic, nodal, extranodal [this includes mucosa
associated lymphoid tissue (MALT)])

- Lymphoplasmacytic lymphoma

- PTCL, relapsed or refractory:

- Anaplastic large cell lymphoma, anaplastic lymphoma kinase (ALK)-positive

- Anaplastic large cell lymphoma, ALK-negative

- Angioimmunoblastic T-cell lymphoma

- Enteropathy-associated T-cell lymphoma

- Extranodal natural killer (NK)/T-cell lymphoma, nasal type

- Hepatosplenic T-cell lymphoma

- PTCL, not otherwise specified (NOS)

- Subcutaneous panniculitis-like T-cell lymphoma

- CTCL:

* CTCL with subtypes of mycosis fungoides Stage IB or higher, Sézary syndrome, or
primary cutaneous anaplastic large cell lymphoma who have failed a previous systemic
treatment, as per the following:

- Stage IA plaque, IB, or IIA: At least 4 prior conventional and/or experimental
regimens (topical or systemic, including psoralen-ultraviolet light [PUVA] and
systemic corticosteroids)

- Stage IIB, III, or IV: At least 1 prior systemic regimen (systemic
corticosteroids alone or PUVA alone do not count as systemic regimens for this
purpose) NOTE: Repeated use of the same regimen is considered 1 regimen

- Prior allogeneic stem cell transplant is allowed provided that all of the following
conditions are met:

- >= 6 months have elapsed since allogeneic transplant

- No Graft vs. Host Disease (GVHD) is present

- Not currently on immunosuppressive therapy

- No prior or concurrent CNS malignancy

PATIENT CHARACTERISTICS:

- ECOG performance status 0-1

- ANC > 1,500/mm^3

- Platelet count > 75,000/mm^3

- Hemoglobin > 7.5 g/dL (transfusion allowed)

- Serum creatinine ≤ 1.2 mg/dL or actual or calculated creatinine clearance > 60 mL/min

- AST and ALT ≤ 2.5 times upper limit of normal (ULN)

- Bilirubin ≤ ULN

- Serum potassium ≥ 3.5 mEq/L (supplementation allowed)

- Serum magnesium ≥ 1.7 mEq/L (supplementation allowed)

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective non-hormonal contraception

- Willing and able to comply with protocol requirements

- No prior severe allergic reactions to bortezomib, boron, mannitol, or romidepsin

- No progressing toxicity secondary to bortezomib

- No grade 1 peripheral neuropathy with pain or ≥ grade 2 peripheral neuropathy by
NCI-CTCAE criteria (v4.0) within the past 14 days

- No condition related to ischemic heart disease, heart failure, or the risk of
torsades de pointes or sudden cardiac death, including any of the following:

- History of sustained ventricular tachycardia, ventricular fibrillation, torsades
de pointes, or resuscitated cardiac arrest unless currently addressed with an
implantable cardiac defibrillator

- Baseline heart rate > 140 beats per minute

- Known congenital long QT syndrome

- QTc interval > 480 milliseconds

- Type II second-degree atrio-ventricular (AV) block, third-degree AV block, or
ventricular rate < 50 beats per minute

- Myocardial infarction within the past 6 months

- Patients who have had a myocardial infarction 6-12 months ago are eligible
provided they are asymptomatic and have a negative cardiac risk assessment
(i.e., treadmill stress test, nuclear medicine stress test, or stress
echocardiogram)

- Angina upon ordinary physical activity

- Angina only with strenuous, rapid, or prolonged exertion allowed

- ECG with evidence of cardiac ischemia, as defined by the following:

- ST depression of ≥ 2 mm, measured from isoelectric line to ST segment

- T-wave inversion ≥ 4 mm, measured from isoelectric line to peak of T-wave

- NYHA class II-IV congestive heart failure

- Known left ventricular ejection fraction < 40% by MUGA scan or < 50% by
echocardiogram or MRI

- Known hypertrophic cardiomegaly or restrictive cardiomyopathy

- No uncontrolled hypertension, defined as persistent blood pressure ≥ 160/95 mm Hg
despite medical management

- No clinically significant active infection, including known HIV infection or
hepatitis B or C

- No other malignancy within the past 3 years except completely resected basal cell
carcinoma or squamous cell carcinoma of the skin, in situ malignancy, or curatively
treated low-risk prostate cancer

- No concurrent medical condition that, in the investigator's opinion, would compromise
study treatment or assessment of toxicity

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- At least 3 weeks since prior chemotherapy, radiation therapy or investigational
agents. If steroids for cancer control have been used, patients must be off theses
agents for at least 1 week before starting treatment. (Maintenance therapy for
non-malignant disease with prednisone or steroid equivalent dose less than 10 mg/day
is permitted)

- Prior allogeneic stem cell transplantation allowed provided all of the following
conditions are met:

- Greater than or equal to 6 months have elapsed since allogeneic transplant

- No Graft vs. Host Disease (GVHD) is present

- More than 4 weeks since prior bortezomib

- No concurrent oral hormonal contraceptives

- No concurrent potent or moderate CYP3A4 inhibitors

- No concurrent anti-arrhythmic agents

- No concurrent treatment with any drugs that are generally accepted to having a risk
of causing torsades de pointes (class 1 drugs)

- Class 2 or 3 drugs allowed at the discretion of the investigator

- No other concurrent systemic therapy for the malignancy

- Concurrent warfarin (coumadin) allowed